EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany

Philipp Mandel, Benedikt Hoeh, Clara Humke, Claudia Doering, Mike Wenzel, Cristina Cano Garcia, Nina Fuhr, Florestan Koll, Anne Fassl, Derya Tilki, Thomas Steuber, Iris Faull und 9 weitere

European Urology Focus · 2024

DOI: 10.1016/j.euf.2024.02.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2024. Verfasst von Philipp Mandel und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: philipp.mandel@kgu…. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Circulating Tumor DNA, Feasibility Studies, Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: With European Medicines Agency approval of PARP inhibitors in metastatic castration-resistant prostate cancer and ongoing trials in metastatic hormone-sensitive prostate cancer, detection of genetic alterations in BRCA1/2 and other homologous recombination repair genes has gained an important role. Our aim was to investigate the feasibility and comparability of comprehensive next-generation sequencing (NGS) of liquid biopsy (LB; circulating tumor DNA) and tumor tissue (TT) samples in a real-world clinical setting. METHODS: The study cohort consisted of 50 patients with metastatic prostate cancer (mPC) who had TT NGS performed for BRCA1/2 alterations and consent for additional LB NGS. The Oncomine Comprehensive Assay v3 (Thermo Fisher Scientific, Waltham, MA, USA) was used for TT NGS. The Guardant360 83-gene assay (Guardant Health, Palo Alto, CA, USA) was used for LB NGS, including all types of somatic alterations, microsatellite instability, and blood tumor mutational burden. We calculated BRCA1/2 alteration rates and the negative percentage agreement (NPA) and positive percentage agreement (PPA) between TT and LB results. KEY FINDINGS AND LIMITATIONS: TT NGS was successful in 44/50 patients (88%), with pathogenic BRCA1/2 alterations detected in four (9%). LB NGS was successful in all 50 patients (100%), with BRCA1/2 alterations detected in ten (20%). In a subgroup analysis for the 44 patients with successful TT NGS, NPA was 85% and PPA was 50%. The median time between TT sample collection and blood sampling for NGS was 132 wk (IQR 94-186). The limited sample size and differences in the time of NGS assessment are limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: LB NGS resulted in a higher detection rate for BRCA1/2 alterations in comparison to conventional TT NGS (20% vs 9%). Ideally, BRCA1/2 testing should be based on both approaches to identify all patients with mPC eligible for PARP inhibitor therapy. PATIENT SUMMARY: Our study shows that genetic tests for both tumor tissue and blood samples results in higher rates of detection of BRCA1/2 gene alterations in patients with metastatic prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingCirculating Tumor DNAFeasibility StudiesProstatic NeoplasmsHumansMaleLiquid BiopsyAgedGermanyMiddle AgedNeoplasm MetastasisBRCA2 ProteinAged, 80 and over

Substanzen

Circulating Tumor DNABRCA2 Protein

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany. Electronic address: philipp.mandel@kgu.de.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospi…
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Guardant Health, Palo Alto, CA, USA.

Förderung

  • Bundesministerium für Bildung und Forschung

Zitieren

APA

Mandel, P., Hoeh, B., Humke, C., Doering, C., Wenzel, M., Cano Garcia, C., Fuhr, N., Koll, F., Fassl, A., Tilki, D., Steuber, T., Faull, I., Jeroch, J., Ebner, S., Schmitt, C., Reis, H., Köllermann, J., Kokkaliaris, K. D., Demes, M. C., …, & Wild, P. J. (2024). Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany. European Urology Focus. https://doi.org/10.1016/j.euf.2024.02.007

Vancouver

Mandel P, Hoeh B, Humke C, Doering C, Wenzel M, Cano Garcia C, et al. Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany. European Urology Focus. 2024. doi:10.1016/j.euf.2024.02.007

BibTeX
@article{Mandel2024,
  author = {Mandel, Philipp and Hoeh, Benedikt and Humke, Clara and Doering, Claudia and Wenzel, Mike and Cano Garcia, Cristina and Fuhr, Nina and Koll, Florestan and Fassl, Anne and Tilki, Derya and Steuber, Thomas and Faull, Iris and Jeroch, Jan and Ebner, Silvana and Schmitt, Christina and Reis, Henning and Köllermann, Jens and Kokkaliaris, Konstantinos D and Demes, Melanie C and Chun, Felix K H and Wild, Peter J},
  title = {Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany},
  journal = {European Urology Focus},
  year = {2024},
  doi = {10.1016/j.euf.2024.02.007}
}
Kostenlos starten →